



GlaxoSmithKline Pharmaceuticals Ltd.  
GSK House,  
Dr. Annie Besant Road, Worli,  
Mumbai - 400 030

Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: www.gsk-india.com  
Email: askus@gsk.com

3<sup>rd</sup> February 2020

To,

**BSE LIMITED**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sir,

**Sub: Unaudited (Standalone and Consolidated) financial results for the third quarter and nine months ended 31<sup>st</sup> December 2019**

Pursuant to Clause 33 read with Clause 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, please find enclosed herewith the Un-Audited Standalone and Consolidated Financial Results and Limited Review Report for the third quarter and nine months ended 31<sup>st</sup> December 2019.

Following the recent decision to initiate a global voluntary recall (pharmacy/retail level) of ranitidine products including Zinetac in India, GSK is continuing with investigations into the potential source of the NDMA and has initiated a comprehensive strategic review of the impact of this recall on all related assets in India. As always, patient safety remains our utmost priority.

Exceptional items recognised in the quarter includes financial impact related to the voluntary recall of Zinetac, as detailed below:

As part of this review, GSK India has assessed the current financial impact of the voluntary recall and has taken a financial impairment of INR 640 crores connected to the under-utilisation of GSK India's manufacturing facilities; and INR 97 crores on account of other related assets / costs. As part of this strategic review, GSK India will explore future options for the Vemgal facility including a potential sale of the site.

The Meeting of the Board of Directors of the Company commenced at 02.00 p.m. and concluded at 06.00 p.m.

This is for your information and record.

Yours faithfully  
**For GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni  
Vice President – Administration, Real Estate  
& Company Secretary

**GlaxoSmithKline Pharmaceuticals Limited**

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030  
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2019**

(Rs. in Lakhs)

Particulars	3 months ended 31.12.19	Preceding 3 months ended 30.09.19	Corresponding 3 months ended 31.12.18	9 months ended 31.12.19	9 months ended 31.12.18	Year ended 31.03.2019
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Income						
1 Revenue from operations	77868	88210	82535	244880	237731	312853
2 Other income	1625	1561	1642	6240	4902	10148
3 <b>Total Income (1+2)</b>	<b>79493</b>	<b>89771</b>	<b>84177</b>	<b>251120</b>	<b>242633</b>	<b>323001</b>
Expenses						
(a) Cost of materials consumed	11245	9456	18491	37605	51382	68207
(b) Purchases of stock-in-trade	23864	13005	22677	66764	54571	64589
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(2334)	14526	(2910)	(1528)	(1109)	2557
(d) Employee benefits expense	16669	14747	12555	45697	39106	53720
(e) Finance costs	298	92	5	483	47	55
(f) Depreciation and amortisation expense	1833	2270	1204	6009	3491	4859
(g) Other expenses	15959	17052	17990	47905	49496	63132
4 <b>Total expenses</b>	<b>67534</b>	<b>71148</b>	<b>70012</b>	<b>202935</b>	<b>196984</b>	<b>257119</b>
5 <b>Profit before exceptional items and tax (3-4)</b>	<b>11959</b>	<b>18623</b>	<b>14165</b>	<b>48185</b>	<b>45649</b>	<b>65882</b>
6 Exceptional items [credit / (charge)] net (Refer Note 3)	(73690)	40114	2813	(33576)	806	489
7 <b>Profit / (Loss) before tax (5+6)</b>	<b>(61731)</b>	<b>58737</b>	<b>16978</b>	<b>14609</b>	<b>46455</b>	<b>66371</b>
8 Tax expense (Refer Note 4)						
(a) Current tax	8062	6521	6859	20224	16467	19282
(b) Deferred tax	(5379)	1937	(1178)	(2826)	(245)	4553
9 <b>Profit / (Loss) for the period/year (7-8)</b>	<b>(64414)</b>	<b>50279</b>	<b>11297</b>	<b>(2789)</b>	<b>30233</b>	<b>42536</b>
10 Other comprehensive income						
(i) Items that will not be reclassified to profit or loss	(361)	(173)	(759)	(534)	(759)	(844)
(ii) Income tax relating to items that will not be reclassified to profit or loss	112	(29)	217	83	217	295
11 <b>Total comprehensive income for the period (9+10)</b>	<b>(64663)</b>	<b>50077</b>	<b>10755</b>	<b>(3240)</b>	<b>29691</b>	<b>41987</b>
Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941	16941	16941
Other equity						197301
Earnings per share (EPS) (of Rs. 10 each)						
Basic and diluted EPS after Exceptional items (Rs.)	(38.02)	29.68	6.67	(1.65)	17.85	25.11
Basic and diluted EPS before Exceptional items (Rs.)	4.25	8.30	5.39	19.25	17.34	25.07
	Not Annualised					




**Notes:**

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 3rd February, 2020.
2. Effective 1st April, 2019, the Company adopted Ind AS 116 "Leases" and applied the same to the lease contracts existing on 1st April, 2019 using the modified retrospective approach, recognizing right-of-use asset and adjusted lease liability. Accordingly, comparatives for the year ended 31st March, 2019 and other periods disclosed have not been retrospectively adjusted. The effect of the adoption is not significant to the result for the period(s).
3. Following the recent decision to initiate a global voluntary recall (pharmacy/retail level) of ranitidine products including Zinetac in India, the Ultimate Holding Company is continuing with investigations into the potential source of the NDMA and has initiated a comprehensive strategic review of the impact of this recall on all related assets in India. As part of the ongoing strategic review, during the quarter, the Company has recognized financial impairment of Rs. 64031 Lacs connected to the under-utilisation of its manufacturing facilities and Rs. 9659 Lacs on account of other related assets / cost. Exceptional items for the quarter ended 31st December, 2018 of Rs. 2813 Lakhs comprise income from profit on sale of property Rs. 2344 Lakhs and sale of brands Rs. 469 Lakhs.
4. The Company has elected to exercise the option permitted u/s 115BAA of the Income- tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019. Accordingly, the Company has recognised Provision for Income tax for the nine months ended 31st December, 2019 and re-measured its net Deferred Tax Assets basis the rate prescribed in the said section. The full impact of this change has been recognised in the Statement of Profit and Loss for the nine months ended 31st December, 2019. Tax expense includes charge on account of exceptional items Rs. 1828 Lakhs, prior year charge of Rs. 2486 Lakhs and impact on net deferred tax due to change in tax rates Rs. 1692 Lakhs of which Rs.50 Lakhs is accounted in Other Comprehensive Income.
5. In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a limited review of the standalone financial results for the quarter and nine months ended 31st December, 2019.
6. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.
7. Previous periods' figures have been re-grouped / re-classified wherever necessary.

3rd February, 2020

By Order of the Board

  
Annaswamy Vaidheesh  
Managing Director  
DIN: 01444303

**GlaxoSmithKline Pharmaceuticals Limited**

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030  
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2019**

(Rs. in Lakhs)

	Particulars	3 months ended	Preceding 3	Corresponding	9 months	9 months	Year ended
		31.12.19	months ended	3 months	ended	ended	31.03.2019
		(Unaudited)	30.09.19	ended 31.12.18	31.12.19	ended 31.12.18	(Audited)
			(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
	Income						
1	Revenue from operations	77859	88202	82535	244858	237731	312812
2	Other income	1650	1588	1658	6319	4960	10232
3	<b>Total Income (1+2)</b>	<b>79509</b>	<b>89790</b>	<b>84193</b>	<b>251177</b>	<b>242691</b>	<b>323044</b>
	Expenses						
	(a) Cost of materials consumed	11245	9456	18491	37605	51832	68657
	(b) Purchases of stock-in-trade	23864	13005	22677	66764	54571	64589
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(2334)	14526	(2910)	(1528)	(1109)	2557
	(d) Employee benefits expense	16669	14747	12555	45697	39106	53720
	(e) Finance costs	298	92	5	483	47	55
	(f) Depreciation and amortisation expense	1833	2270	1204	6009	3491	4859
	(g) Other expenses	15976	17067	18007	47951	49550	63210
4	<b>Total expenses</b>	<b>67551</b>	<b>71163</b>	<b>70029</b>	<b>202981</b>	<b>197488</b>	<b>257647</b>
5	<b>Profit before exceptional items and tax (3-4)</b>	<b>11958</b>	<b>18627</b>	<b>14164</b>	<b>48196</b>	<b>45203</b>	<b>65397</b>
6	Exceptional items [credit / (charge)] net (Refer Note 3)	(75390)	40114	2884	(35276)	877	2869
7	<b>Profit / (Loss) before tax (5+6)</b>	<b>(63432)</b>	<b>58741</b>	<b>17048</b>	<b>12920</b>	<b>46080</b>	<b>68266</b>
8	Tax expense (Refer Note 4)						
	(a) Current tax	8062	6521	6859	20224	16467	19282
	(b) Deferred tax	(5378)	1945	(1178)	(2817)	(245)	4445
9	<b>Profit / (Loss) for the period/year (7-8)</b>	<b>(66116)</b>	<b>50275</b>	<b>11367</b>	<b>(4487)</b>	<b>29858</b>	<b>44539</b>
10	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss	(361)	(173)	(759)	(534)	(759)	(844)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	112	(29)	217	83	217	295
11	<b>Total comprehensive income for the period (9+10)</b>	<b>(66365)</b>	<b>50073</b>	<b>10825</b>	<b>(4938)</b>	<b>29316</b>	<b>43990</b>
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941	16941	16941
	Other equity						197042
	Earnings per share (EPS) (of Rs. 10 each)						
	Basic and diluted EPS after Exceptional items (Rs.)	(39.03)	29.68	6.71	(2.65)	17.63	26.29
	Basic and diluted EPS before Exceptional items (Rs.)	4.25	8.30	5.39	19.25	17.08	24.85
				Not Annualised			






**Notes:**

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 3rd February, 2020.
2. Effective 1st April, 2019, the Group adopted Ind AS 116 "Leases" and applied the same to the lease contracts existing on 1st April, 2019 using the modified retrospective approach, recognizing right-of-use asset and adjusted lease liability. Accordingly, comparatives for the year ended 31st March, 2019 and other periods disclosed have not been retrospectively adjusted. The effect of the adoption is not significant to the result for the period(s).
3. Following the recent decision to initiate a global voluntary recall (pharmacy/retail level) of ranitidine products including Zinetac in India, the Ultimate Holding Company is continuing with investigations into the potential source of the NDMA and has initiated a comprehensive strategic review of the impact of this recall on all related assets in India. As part of the ongoing strategic review, during the quarter, the holding company has recognized financial impairment of Rs. 64031 Lakhs connected to the under-utilisation of its manufacturing facilities and Rs. 9659 Lakhs on account of other related assets / cost. Also charge of Rs. 1700 Lakhs is recognised by Biddle Sawyer Limited (Subsidiary) on account of outstanding litigation matter.  
Exceptional items for the quarter ended 31st December, 2018 of Rs. 2884 Lakhs comprise income from profit on sale of property Rs. 2344 Lakhs and sale of brands Rs. 540 Lakhs.
4. The Parent has elected to exercise the option permitted u/s 115BAA of the Income- tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019. Accordingly, the Parent has recognised Provision for Income tax for the nine months ended 31st December, 2019 and re-measured its net Deferred Tax Assets basis the rate prescribed in the said section. The full impact of this change has been recognised in the Statement of Profit and Loss for the nine months ended 31st December, 2019. Tax expense includes charge on account of exceptional items Rs. 1828 Lakhs, prior year charge of Rs. 2486 Lakhs and impact on net deferred tax due to change in tax rates Rs. 1692 Lakhs of which Rs.50 Lakhs is accounted in Other Comprehensive Income.
5. In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a limited review of the consolidated financial results for the quarter and nine months ended 31st December, 2019.
6. The Group has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.
7. Previous periods' figures have been re-grouped / re-classified wherever necessary.

3rd February, 2020

By Order of the Board

  
Annaswamy Vaidheesh  
Managing Director  
DIN: 01444303

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM  
STANDALONE FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **GLAXOSMITHKLINE PHARMACEUTICALS LIMITED** ("the Company"), for the quarter and nine months ended 31<sup>st</sup> December, 2019 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Rupen K. Bhatt  
Partner  
(Membership No. 046930)

UDIN: 20046930AAAAA46117



Place: MUMBAI  
Date: February 3, 2020



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF  
INTERIM CONSOLIDATED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **GLAXOSMITHKLINE PHARMACEUTICALS LIMITED** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the quarter and nine months ended 31<sup>st</sup> December, 2019 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.  
  
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the subsidiary – Biddle Sawyer Limited.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of another auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing



**Deloitte  
Haskins & Sells LLP**

Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial results of the subsidiary included in the consolidated unaudited financial results, whose financial results reflect total revenues of Rs. NIL and Rs. NIL for the quarter and nine months ended 31<sup>st</sup> December, 2019 respectively, total net loss after tax of Rs. 17,01 lacs and Rs. 16,97 lacs for the quarter and nine months ended 31<sup>st</sup> December, 2019 respectively and total comprehensive loss of Rs. 17,01 lacs and Rs. 16,97 lacs for the quarter and nine months ended December 31, 2019 respectively, as considered in the Statement. These financial results have been reviewed by another auditor whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of another auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)

Rupen K. Bhatt  
Partner  
(Membership No. 046930)  
UDIN: 20046930 AAAAII 4053

Place: MUMBAI  
Date: February 3, 2020